If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> DIABETES<br /> ISSN 2054-6181 Vol 5.1 • October 2017 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> EASD 2017<br /> Lisbon, Portugal<br /> CONTENTS<br /> EDITORIAL BOARD...................................................................................................................................... 4<br /> CONGRESS REVIEW..................................................................................................................................... 12<br /> • Review of the European Association for the Study of Diabetes (EASD) 53rd Annual<br /> Meeting 2017, held in Lisbon, Portugal, 11th–15th September 2017<br /> INTERVIEWS WITH EMJ DIABETES EDITORIAL BOARD.................................................................... 28<br /> SYMPOSIUM REVIEWS<br /> • SESSION ONE: BASAL INSULINS: STILL INNOVATING AFTER ALL THESE YEARS............... 38<br /> • SESSION TWO: CH<a title="EMJ Diabetes 5.1 2017 page 1" href="http://viewer.zmags.com/publication/3b16c228?page=1"> DIABETES ISSN 2054-6181 </a> <a title="EMJ Diabetes 5.1 2017 page 2" href="http://viewer.zmags.com/publication/3b16c228?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Diabetes 5.1 2017 page 3" href="http://viewer.zmags.com/publication/3b16c228?page=3"> DIABETES • FUTURE TREATMENTS OF DIABETIC RETI</a> <a title="EMJ Diabetes 5.1 2017 page 4" href="http://viewer.zmags.com/publication/3b16c228?page=4"> EDITORIAL BOARD EDITOR-IN-CHIEF Prof Jörg Huber</a> <a title="EMJ Diabetes 5.1 2017 page 5" href="http://viewer.zmags.com/publication/3b16c228?page=5"> DIABETES AIMS AND SCOPE • The European Me</a> <a title="EMJ Diabetes 5.1 2017 page 6" href="http://viewer.zmags.com/publication/3b16c228?page=6"> DIABETES 5.1 OCTOBER 2017 Director Spencer Gore</a> <a title="EMJ Diabetes 5.1 2017 page 7" href="http://viewer.zmags.com/publication/3b16c228?page=7"> Welcome Hello, and a wholehearted welcome to a</a> <a title="EMJ Diabetes 5.1 2017 page 8" href="http://viewer.zmags.com/publication/3b16c228?page=8"> europeanmedical-journal.com EUROPEAN UNION Invest</a> <a title="EMJ Diabetes 5.1 2017 page 9" href="http://viewer.zmags.com/publication/3b16c228?page=9"> Foreword Prof Jörg Huber Res</a> <a title="EMJ Diabetes 5.1 2017 page 10" href="http://viewer.zmags.com/publication/3b16c228?page=10"> European Medical Journal 2.1 2017 </a> <a title="EMJ Diabetes 5.1 2017 page 11" href="http://viewer.zmags.com/publication/3b16c228?page=11"> FEATURE Climate Change: What Can Doctors Do? • </a> <a title="EMJ Diabetes 5.1 2017 page 12" href="http://viewer.zmags.com/publication/3b16c228?page=12"> </a> <a title="EMJ Diabetes 5.1 2017 page 13" href="http://viewer.zmags.com/publication/3b16c228?page=13"> EASD ANNUAL CONGRESS 2017 FIL - FEIRA INTERNACIO</a> <a title="EMJ Diabetes 5.1 2017 page 14" href="http://viewer.zmags.com/publication/3b16c228?page=14"> of knowledge of diabetes and related metabo</a> <a title="EMJ Diabetes 5.1 2017 page 15" href="http://viewer.zmags.com/publication/3b16c228?page=15"> Study Associates Sodium Intake with Type 2 Diabet</a> <a title="EMJ Diabetes 5.1 2017 page 16" href="http://viewer.zmags.com/publication/3b16c228?page=16"> in a press release dated 14th September, 20</a> <a title="EMJ Diabetes 5.1 2017 page 17" href="http://viewer.zmags.com/publication/3b16c228?page=17"> We believe further research is required to guide </a> <a title="EMJ Diabetes 5.1 2017 page 18" href="http://viewer.zmags.com/publication/3b16c228?page=18"> Results found no statistically significant</a> <a title="EMJ Diabetes 5.1 2017 page 19" href="http://viewer.zmags.com/publication/3b16c228?page=19"> The study found patients had a significant, averag</a> <a title="EMJ Diabetes 5.1 2017 page 20" href="http://viewer.zmags.com/publication/3b16c228?page=20"> These results suggest that increased frequency of</a> <a title="EMJ Diabetes 5.1 2017 page 21" href="http://viewer.zmags.com/publication/3b16c228?page=21"> Transgender Diabetics Require More Specialist Sup</a> <a title="EMJ Diabetes 5.1 2017 page 22" href="http://viewer.zmags.com/publication/3b16c228?page=22"> Because non-alcoholic fatty liver independently r</a> <a title="EMJ Diabetes 5.1 2017 page 23" href="http://viewer.zmags.com/publication/3b16c228?page=23"> research group, also discovered T2DM patients to </a> <a title="EMJ Diabetes 5.1 2017 page 24" href="http://viewer.zmags.com/publication/3b16c228?page=24"> also 17, 28, and 38 years of age for the three ge</a> <a title="EMJ Diabetes 5.1 2017 page 25" href="http://viewer.zmags.com/publication/3b16c228?page=25"> babies (53% compared to 69%), reduced neonat</a> <a title="EMJ Diabetes 5.1 2017 page 26" href="http://viewer.zmags.com/publication/3b16c228?page=26"> Delivery of the baby is currently the</a> <a title="EMJ Diabetes 5.1 2017 page 27" href="http://viewer.zmags.com/publication/3b16c228?page=27"> Would you like to write for the EMJ blog? Interac</a> <a title="EMJ Diabetes 5.1 2017 page 28" href="http://viewer.zmags.com/publication/3b16c228?page=28"> Martijn Brouwers Internist-endocrinologist, Depa</a> <a title="EMJ Diabetes 5.1 2017 page 29" href="http://viewer.zmags.com/publication/3b16c228?page=29"> Q: One of your particular interests is in providi</a> <a title="EMJ Diabetes 5.1 2017 page 30" href="http://viewer.zmags.com/publication/3b16c228?page=30"> stimulation of the sympathetic nervous syste</a> <a title="EMJ Diabetes 5.1 2017 page 31" href="http://viewer.zmags.com/publication/3b16c228?page=31"> crosstalk (gut-adipose, tissue-muscle) in obe</a> <a title="EMJ Diabetes 5.1 2017 page 32" href="http://viewer.zmags.com/publication/3b16c228?page=32"> polyphenols or other functional foods may help in</a> <a title="EMJ Diabetes 5.1 2017 page 33" href="http://viewer.zmags.com/publication/3b16c228?page=33"> Within the context of a healthy lifestyle, I thin</a> <a title="EMJ Diabetes 5.1 2017 page 34" href="http://viewer.zmags.com/publication/3b16c228?page=34"> medical and dentistry students, as well as </a> <a title="EMJ Diabetes 5.1 2017 page 35" href="http://viewer.zmags.com/publication/3b16c228?page=35"> A: Scientific organisations are very importan</a> <a title="EMJ Diabetes 5.1 2017 page 36" href="http://viewer.zmags.com/publication/3b16c228?page=36"> The new treatments with newer antidiabetic medica</a> <a title="EMJ Diabetes 5.1 2017 page 37" href="http://viewer.zmags.com/publication/3b16c228?page=37"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Diabetes 5.1 2017 page 38" href="http://viewer.zmags.com/publication/3b16c228?page=38"> SESSION 1: BASAL INSULINS: STILL </a> <a title="EMJ Diabetes 5.1 2017 page 39" href="http://viewer.zmags.com/publication/3b16c228?page=39"> to the current gold standard glycated haemoglobin</a> <a title="EMJ Diabetes 5.1 2017 page 40" href="http://viewer.zmags.com/publication/3b16c228?page=40"> world patients with diabetes face many challenges</a> <a title="EMJ Diabetes 5.1 2017 page 41" href="http://viewer.zmags.com/publication/3b16c228?page=41"> Insulin injection 80 Blood glucose (mg/dL) 0</a> <a title="EMJ Diabetes 5.1 2017 page 42" href="http://viewer.zmags.com/publication/3b16c228?page=42"> Claims database RCT supplement </a> <a title="EMJ Diabetes 5.1 2017 page 43" href="http://viewer.zmags.com/publication/3b16c228?page=43"> that patients remain poorly controlled on O</a> <a title="EMJ Diabetes 5.1 2017 page 44" href="http://viewer.zmags.com/publication/3b16c228?page=44"> that were consistent with reductions observed wit</a> <a title="EMJ Diabetes 5.1 2017 page 45" href="http://viewer.zmags.com/publication/3b16c228?page=45"> accessed: 6 September 2017. 20. Gliklich RE, </a> <a title="EMJ Diabetes 5.1 2017 page 46" href="http://viewer.zmags.com/publication/3b16c228?page=46"> SESSION 2: CHANGING THE TYPE 2 DIABETES MELLITU</a> <a title="EMJ Diabetes 5.1 2017 page 47" href="http://viewer.zmags.com/publication/3b16c228?page=47"> plus a glucagon-like peptide 1 receptor agonist (</a> <a title="EMJ Diabetes 5.1 2017 page 48" href="http://viewer.zmags.com/publication/3b16c228?page=48"> populations and, despite differences in stud</a> <a title="EMJ Diabetes 5.1 2017 page 49" href="http://viewer.zmags.com/publication/3b16c228?page=49"> Evidence for Fixed-Ratio Basal Insulin/ Glucagon-</a> <a title="EMJ Diabetes 5.1 2017 page 50" href="http://viewer.zmags.com/publication/3b16c228?page=50"> Who Can Benefit and How to Use: Assessing</a> <a title="EMJ Diabetes 5.1 2017 page 51" href="http://viewer.zmags.com/publication/3b16c228?page=51"> • Injectable therapies, including basal insulin</a> <a title="EMJ Diabetes 5.1 2017 page 52" href="http://viewer.zmags.com/publication/3b16c228?page=52"> Type 2 diabetes mellitus (N=2,470), in whic</a> <a title="EMJ Diabetes 5.1 2017 page 53" href="http://viewer.zmags.com/publication/3b16c228?page=53"> LS mean change in HbA1c (%) 0.0 -0.2 -0.4 -0.6 -</a> <a title="EMJ Diabetes 5.1 2017 page 54" href="http://viewer.zmags.com/publication/3b16c228?page=54"> library/EPAR_-_Product_Information/ human/002647/</a> <a title="EMJ Diabetes 5.1 2017 page 55" href="http://viewer.zmags.com/publication/3b16c228?page=55"> treatment of type 2 diabetes: A rando</a> <a title="EMJ Diabetes 5.1 2017 page 56" href="http://viewer.zmags.com/publication/3b16c228?page=56"> SESSION 3: INNOVATING BEYOND GLUCOSE CONTRO</a> <a title="EMJ Diabetes 5.1 2017 page 57" href="http://viewer.zmags.com/publication/3b16c228?page=57"> MEETING SUMMARY Advances in treatment offerings a</a> <a title="EMJ Diabetes 5.1 2017 page 58" href="http://viewer.zmags.com/publication/3b16c228?page=58"> • Preliminary evidence generated from analyses </a> <a title="EMJ Diabetes 5.1 2017 page 59" href="http://viewer.zmags.com/publication/3b16c228?page=59"> To date, several CV outcomes trials have b</a> <a title="EMJ Diabetes 5.1 2017 page 60" href="http://viewer.zmags.com/publication/3b16c228?page=60"> HbA1c was 7.5%.2 Approximately 75% of patients we</a> <a title="EMJ Diabetes 5.1 2017 page 61" href="http://viewer.zmags.com/publication/3b16c228?page=61"> ODYSSEY DM-DYSLIPIDEMIA was a randomised, dou</a> <a title="EMJ Diabetes 5.1 2017 page 62" href="http://viewer.zmags.com/publication/3b16c228?page=62"> (DKA) and uncharacteristically mild-to-moderat</a> <a title="EMJ Diabetes 5.1 2017 page 63" href="http://viewer.zmags.com/publication/3b16c228?page=63"> Unmet Needs in Adult Patients with Type 1 Diabete</a> <a title="EMJ Diabetes 5.1 2017 page 64" href="http://viewer.zmags.com/publication/3b16c228?page=64"> (70–180 mg/dL). In addition, there was no increas</a> <a title="EMJ Diabetes 5.1 2017 page 65" href="http://viewer.zmags.com/publication/3b16c228?page=65"> The study comprised a 2-week screening period, 2-</a> <a title="EMJ Diabetes 5.1 2017 page 66" href="http://viewer.zmags.com/publication/3b16c228?page=66"> quantitative data on the differential effect</a> <a title="EMJ Diabetes 5.1 2017 page 67" href="http://viewer.zmags.com/publication/3b16c228?page=67"> metrics of success that are affordable, accessibl</a> <a title="EMJ Diabetes 5.1 2017 page 68" href="http://viewer.zmags.com/publication/3b16c228?page=68"> physicians’ working hours, data can be transmitte</a> <a title="EMJ Diabetes 5.1 2017 page 69" href="http://viewer.zmags.com/publication/3b16c228?page=69"> DM-DYSLIPIDEMIA trial: Lipid-lowering efficacy </a> <a title="EMJ Diabetes 5.1 2017 page 70" href="http://viewer.zmags.com/publication/3b16c228?page=70"> Abstract Reviews A ROLE FOR CONNEXIN </a> <a title="EMJ Diabetes 5.1 2017 page 71" href="http://viewer.zmags.com/publication/3b16c228?page=71"> EASD 2017 In conclusion, our study reports that </a> <a title="EMJ Diabetes 5.1 2017 page 72" href="http://viewer.zmags.com/publication/3b16c228?page=72"> Abstract Reviews Females Males T2DM </a> <a title="EMJ Diabetes 5.1 2017 page 73" href="http://viewer.zmags.com/publication/3b16c228?page=73"> EASD 2017 linkage study. PLoS Med. 2012;9(10):e1</a> <a title="EMJ Diabetes 5.1 2017 page 74" href="http://viewer.zmags.com/publication/3b16c228?page=74"> Abstract Reviews Table 1: Clinical and laboratory</a> <a title="EMJ Diabetes 5.1 2017 page 75" href="http://viewer.zmags.com/publication/3b16c228?page=75"> EASD 2017 47.8%, respectively (р=0.76). Renin</a> <a title="EMJ Diabetes 5.1 2017 page 76" href="http://viewer.zmags.com/publication/3b16c228?page=76"> Abstract Reviews Society (DDG) for making her pa</a> <a title="EMJ Diabetes 5.1 2017 page 77" href="http://viewer.zmags.com/publication/3b16c228?page=77"> EASD 2017 2. Hall KD et al. Calorie for calorie,</a> <a title="EMJ Diabetes 5.1 2017 page 78" href="http://viewer.zmags.com/publication/3b16c228?page=78"> Abstract Reviews (PBO) or DAPA plus PBO, with no</a> <a title="EMJ Diabetes 5.1 2017 page 79" href="http://viewer.zmags.com/publication/3b16c228?page=79"> EASD 2017 Disclosure: This research has been con</a> <a title="EMJ Diabetes 5.1 2017 page 80" href="http://viewer.zmags.com/publication/3b16c228?page=80"> Abstract Reviews Our genetic study suggests that</a> <a title="EMJ Diabetes 5.1 2017 page 81" href="http://viewer.zmags.com/publication/3b16c228?page=81"> EASD 2017 A B Figure 1: SOCS2-/- macrosomic phen</a> <a title="EMJ Diabetes 5.1 2017 page 82" href="http://viewer.zmags.com/publication/3b16c228?page=82"> Abstract Reviews VOLUNTARY EXERCISE CAN MODIFY </a> <a title="EMJ Diabetes 5.1 2017 page 83" href="http://viewer.zmags.com/publication/3b16c228?page=83"> EASD 2017 Palatable food in obesity under seden</a> <a title="EMJ Diabetes 5.1 2017 page 84" href="http://viewer.zmags.com/publication/3b16c228?page=84"> EDITOR’S PICK The Editor’s Pick for </a> <a title="EMJ Diabetes 5.1 2017 page 85" href="http://viewer.zmags.com/publication/3b16c228?page=85"> pressure (BP) goals in persons with DM to </a> <a title="EMJ Diabetes 5.1 2017 page 86" href="http://viewer.zmags.com/publication/3b16c228?page=86"> such as diabetic nephropathy. The benefi</a> <a title="EMJ Diabetes 5.1 2017 page 87" href="http://viewer.zmags.com/publication/3b16c228?page=87"> Table 1: A summary of the clinical trial data on </a> <a title="EMJ Diabetes 5.1 2017 page 88" href="http://viewer.zmags.com/publication/3b16c228?page=88"> stroke; and 0.3% versus 0.47%; HR: 0.63; 95% CI: </a> <a title="EMJ Diabetes 5.1 2017 page 89" href="http://viewer.zmags.com/publication/3b16c228?page=89"> Table 2: Recommendations for management of hypert</a> <a title="EMJ Diabetes 5.1 2017 page 90" href="http://viewer.zmags.com/publication/3b16c228?page=90"> placebo (9.3% versus 10.5%), whereas ARB did not </a> <a title="EMJ Diabetes 5.1 2017 page 91" href="http://viewer.zmags.com/publication/3b16c228?page=91"> Recent data from several randomised clinical tria</a> <a title="EMJ Diabetes 5.1 2017 page 92" href="http://viewer.zmags.com/publication/3b16c228?page=92"> blood pressure in adults: Report from the panel </a> <a title="EMJ Diabetes 5.1 2017 page 93" href="http://viewer.zmags.com/publication/3b16c228?page=93"> FUTURE TREATMENTS OF DIABETIC RETINOPATHY: </a> <a title="EMJ Diabetes 5.1 2017 page 94" href="http://viewer.zmags.com/publication/3b16c228?page=94"> regimens can be challenging. Drugs that can</a> <a title="EMJ Diabetes 5.1 2017 page 95" href="http://viewer.zmags.com/publication/3b16c228?page=95"> achieved with intravitreal anti-VEGF antibodi</a> <a title="EMJ Diabetes 5.1 2017 page 96" href="http://viewer.zmags.com/publication/3b16c228?page=96"> The ongoing Phase II trial is using 0.75 </a> <a title="EMJ Diabetes 5.1 2017 page 97" href="http://viewer.zmags.com/publication/3b16c228?page=97"> Table 2 continued. Drug Clinical phase Im</a> <a title="EMJ Diabetes 5.1 2017 page 98" href="http://viewer.zmags.com/publication/3b16c228?page=98"> and proinflammatory cytokines, but facilitates</a> <a title="EMJ Diabetes 5.1 2017 page 99" href="http://viewer.zmags.com/publication/3b16c228?page=99"> In a Phase I, dose-escalation study (doses rangin</a> <a title="EMJ Diabetes 5.1 2017 page 100" href="http://viewer.zmags.com/publication/3b16c228?page=100"> development of DR. In a randomised trial, </a> <a title="EMJ Diabetes 5.1 2017 page 101" href="http://viewer.zmags.com/publication/3b16c228?page=101"> with the primary endpoint analysis at 6 months. E</a> <a title="EMJ Diabetes 5.1 2017 page 102" href="http://viewer.zmags.com/publication/3b16c228?page=102"> 29. Chhablani J et al. Short-term safety profile </a> <a title="EMJ Diabetes 5.1 2017 page 103" href="http://viewer.zmags.com/publication/3b16c228?page=103"> Pharmaceuticals Wins £2.4m Biomedical Catalyst Gr</a> <a title="EMJ Diabetes 5.1 2017 page 104" href="http://viewer.zmags.com/publication/3b16c228?page=104"> ROLE OF PROBIOTICS IN DIABETES: A REV</a> <a title="EMJ Diabetes 5.1 2017 page 105" href="http://viewer.zmags.com/publication/3b16c228?page=105"> The objective of this review was to first understa</a> <a title="EMJ Diabetes 5.1 2017 page 106" href="http://viewer.zmags.com/publication/3b16c228?page=106"> bacterial fragments also diffuse through </a> <a title="EMJ Diabetes 5.1 2017 page 107" href="http://viewer.zmags.com/publication/3b16c228?page=107"> Furthermore, when the mice were given a high- fat</a> <a title="EMJ Diabetes 5.1 2017 page 108" href="http://viewer.zmags.com/publication/3b16c228?page=108"> levels, blunting of glucose excursions on t</a> <a title="EMJ Diabetes 5.1 2017 page 109" href="http://viewer.zmags.com/publication/3b16c228?page=109"> Table 2: Overview of important clinical studies d</a> <a title="EMJ Diabetes 5.1 2017 page 110" href="http://viewer.zmags.com/publication/3b16c228?page=110"> 9. Langdon A et al. The effects of </a> <a title="EMJ Diabetes 5.1 2017 page 111" href="http://viewer.zmags.com/publication/3b16c228?page=111"> TYPE 2 DIABETES MELLITUS AND STEM CELL THERAPY: A</a> <a title="EMJ Diabetes 5.1 2017 page 112" href="http://viewer.zmags.com/publication/3b16c228?page=112"> to peripheral insulin resistance. Another compone</a> <a title="EMJ Diabetes 5.1 2017 page 113" href="http://viewer.zmags.com/publication/3b16c228?page=113"> Table 1: Clinical trials using bone marrow hemato</a> <a title="EMJ Diabetes 5.1 2017 page 114" href="http://viewer.zmags.com/publication/3b16c228?page=114"> diabetes, partially or completely in some cases, </a> <a title="EMJ Diabetes 5.1 2017 page 115" href="http://viewer.zmags.com/publication/3b16c228?page=115"> The fate of the infused cells was explored by Soo</a> <a title="EMJ Diabetes 5.1 2017 page 116" href="http://viewer.zmags.com/publication/3b16c228?page=116"> of different stem cells being tried. Due to most </a> <a title="EMJ Diabetes 5.1 2017 page 117" href="http://viewer.zmags.com/publication/3b16c228?page=117"> placebo-controlled study. Cell Transplant. 2014;2</a> <a title="EMJ Diabetes 5.1 2017 page 118" href="http://viewer.zmags.com/publication/3b16c228?page=118"> ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY I</a> <a title="EMJ Diabetes 5.1 2017 page 119" href="http://viewer.zmags.com/publication/3b16c228?page=119"> Table 1: Summary of molecular differences between</a> <a title="EMJ Diabetes 5.1 2017 page 120" href="http://viewer.zmags.com/publication/3b16c228?page=120"> residual oedema (Table 2).7 Despite improvements </a> <a title="EMJ Diabetes 5.1 2017 page 121" href="http://viewer.zmags.com/publication/3b16c228?page=121"> After 12 months, all remaining patients wer</a> <a title="EMJ Diabetes 5.1 2017 page 122" href="http://viewer.zmags.com/publication/3b16c228?page=122"> efficacy.19 Two noteworthy points not seen in RCT</a> <a title="EMJ Diabetes 5.1 2017 page 123" href="http://viewer.zmags.com/publication/3b16c228?page=123"> improvements in mean BCVA and mean CRT with pegap</a> <a title="EMJ Diabetes 5.1 2017 page 124" href="http://viewer.zmags.com/publication/3b16c228?page=124"> Furthermore, current evidence strongly supports t</a> <a title="EMJ Diabetes 5.1 2017 page 125" href="http://viewer.zmags.com/publication/3b16c228?page=125"> 118(4):615-25. 11. Schmidt-Erfurth U et al.; REST</a> <a title="EMJ Diabetes 5.1 2017 page 126" href="http://viewer.zmags.com/publication/3b16c228?page=126"> ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERA</a> <a title="EMJ Diabetes 5.1 2017 page 127" href="http://viewer.zmags.com/publication/3b16c228?page=127"> which are effective but associated with increased</a> <a title="EMJ Diabetes 5.1 2017 page 128" href="http://viewer.zmags.com/publication/3b16c228?page=128"> only antigen binding domains specific to all</a> <a title="EMJ Diabetes 5.1 2017 page 129" href="http://viewer.zmags.com/publication/3b16c228?page=129"> RISE/RIDE RISE/RIDE were two parallel, method</a> <a title="EMJ Diabetes 5.1 2017 page 130" href="http://viewer.zmags.com/publication/3b16c228?page=130"> VEGF-A, VEGF-B, and placental growth factor.</a> <a title="EMJ Diabetes 5.1 2017 page 131" href="http://viewer.zmags.com/publication/3b16c228?page=131"> Pegaptanib Pegaptanib sodium (Macugen™, </a> <a title="EMJ Diabetes 5.1 2017 page 132" href="http://viewer.zmags.com/publication/3b16c228?page=132"> option, even after using an analytical model to a</a> <a title="EMJ Diabetes 5.1 2017 page 133" href="http://viewer.zmags.com/publication/3b16c228?page=133"> bevacizumab for diabetic macular oedema:</a> <a title="EMJ Diabetes 5.1 2017 page 134" href="http://viewer.zmags.com/publication/3b16c228?page=134"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Diabetes 5.1 2017 page 135" href="http://viewer.zmags.com/publication/3b16c228?page=135"> Buyer’s Guide • A. MENARINI DIAGNOSTICS SRL </a> <a title="EMJ Diabetes 5.1 2017 page 136" href="http://viewer.zmags.com/publication/3b16c228?page=136"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NEW</a>